Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Sharad A Ghamande"'
Autor:
Jinhua Wang, Ashok Sharma, Sharad A Ghamande, Stephen Bush, Daron Ferris, Wenbo Zhi, Mingfang He, Meiyao Wang, Xiaoxiao Wang, Eric Miller, Diane Hopkins, Michael Macfee, Ruili Guan, Jinhai Tang, Jin-Xiong She
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78393 (2013)
BACKGROUND: Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome and recurrence of cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused on the discovery and validation of diagnost
Externí odkaz:
https://doaj.org/article/2eddd7ae20fb439e97c05c749be0288b
Autor:
Jon A. Hoin, Bradley C. Carthon, Shantoria J. Brown, Lynn M. Durham, L. Crain Garrot, Sharad A. Ghamande, Andrew W. Pippas, Brian M. Rivers, Cindy T. Snyder, Sheryl Gordon Ann Gabram-Mendola
Publikováno v:
Frontiers in Health Services, Vol 4 (2024)
The Georgia Center for Oncology Research and Education (Georgia CORE) and the Georgia Society of Clinical Oncology (GASCO) held a one-day summit exploring opportunities and evidence-based interventions to address disparities in cancer clinical trials
Externí odkaz:
https://doaj.org/article/4a678458107a4864954d13a39ad093ff
Autor:
Mansoor R. Mirza, Antonio González‐Martín, Whitney S. Graybill, David M. O’Malley, Lydia Gaba, Oi Wah Stephanie Yap, Eva M. Guerra, Peter G. Rose, Jean‐François Baurain, Sharad A. Ghamande, Hannelore Denys, Emily Prendergast, Carmela Pisano, Philippe Follana, Klaus Baumann, Paula M. Calvert, Jacob Korach, Yong Li, Izabela A. Malinowska, Divya Gupta, Bradley J. Monk
Publikováno v:
CANCER
Background: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c5da21c2393f06a49b3747604165ac
https://doi.org/10.1002/cncr.34706
https://doi.org/10.1002/cncr.34706
Autor:
Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria-Jesús Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, José A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio González-Martín, Brian Slomovitz, Yan Jia, Lisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote
Publikováno v:
Gynecologic oncology
Objective. The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-alpha monoclonal antibody, improved progression-free survival (PFS) versus placebo when added to standard chemo-therapy regimens in patients with pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e49e0788b9e531ebeea795ae16ee810c
https://doi.org/10.1016/j.ygyno.2023.01.003
https://doi.org/10.1016/j.ygyno.2023.01.003
Autor:
Karen A. Cadoo, David R. Spigel, Suzanne F. Jones, Juliann Chmielecki, Zhongwu Lai, Ganesh M. Mugundu, Sanjeev Kumar, Esteban Rodrigo Imedio, Janiel M. Cragun, Tiffany A. Troso-Sandoval, Jill J.J. Geenen, Daniel L. Spitz, Steven C. Plaxe, Gottfried E. Konecny, Sharad A. Ghamande, Amit M. Oza, Lee-may Chen, Erika P. Hamilton, Setsuko K. Chambers, Kathleen N. Moore
Supplementary tables S1-S3 and Supplementary figures S1-Se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55af112ceb8321e8d2dd7167f8a42155
https://doi.org/10.1158/1078-0432.22484450.v1
https://doi.org/10.1158/1078-0432.22484450.v1
Autor:
W. Martin Kast, Michael J. Birrer, Russell J. Schilder, Yvonne G. Lin, Sharad A. Ghamande, Katherine M. Moxley, Heather A. Lankes, Huyen Q. Pham, Koji Matsuo, Joseph G. Skeate, Jyoti S. Mayadev, Danielle M. Enserro, Diane M. Da Silva
Figure S6 shows the association of circulating cytokine levels with objective clinical response.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::748bd579da819603297f00f53f6e086a
https://doi.org/10.1158/1078-0432.22476128.v1
https://doi.org/10.1158/1078-0432.22476128.v1
Autor:
Karen A. Cadoo, David R. Spigel, Suzanne F. Jones, Juliann Chmielecki, Zhongwu Lai, Ganesh M. Mugundu, Sanjeev Kumar, Esteban Rodrigo Imedio, Janiel M. Cragun, Tiffany A. Troso-Sandoval, Jill J.J. Geenen, Daniel L. Spitz, Steven C. Plaxe, Gottfried E. Konecny, Sharad A. Ghamande, Amit M. Oza, Lee-may Chen, Erika P. Hamilton, Setsuko K. Chambers, Kathleen N. Moore
Purpose:This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer.Patients and Methods:Women with histologically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329c4cb04a3b96cf79664f7505b8f71f
https://doi.org/10.1158/1078-0432.c.6530816
https://doi.org/10.1158/1078-0432.c.6530816
Autor:
W. Martin Kast, Michael J. Birrer, Russell J. Schilder, Yvonne G. Lin, Sharad A. Ghamande, Katherine M. Moxley, Heather A. Lankes, Huyen Q. Pham, Koji Matsuo, Joseph G. Skeate, Jyoti S. Mayadev, Danielle M. Enserro, Diane M. Da Silva
Purpose:A phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune-modulation therapy with the checkpoint inhibitor ipilimumab [anti–CTL antigen-4 (anti–CTLA-4)] following chemoradiation therapy (CRT) for newly diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af187ea51a0b6c31d398ef4b937f2a2
https://doi.org/10.1158/1078-0432.c.6529304
https://doi.org/10.1158/1078-0432.c.6529304
Autor:
Karen Cadoo, Steven C. Plaxe, Janiel M. Cragun, Esteban Rodrigo Imedio, Setsuko K. Chambers, Ganesh Mugundu, Jill J.J. Geenen, Gottfried E. Konecny, Suzanne F. Jones, Lee-may Chen, Tiffany A. Troso-Sandoval, Erika Hamilton, Zhongwu Lai, David R. Spigel, Kathleen N. Moore, Amit M. Oza, Sharad A. Ghamande, Daniel Lewis Spitz, Sanjeev Kumar, Juliann Chmielecki
Publikováno v:
Clinical Cancer Research. 28:36-44
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. Patients and Methods: Women with histologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b0f9e79e117413e55f91e3d89d74b2f
https://doi.org/10.1158/1078-0432.ccr-21-0158
https://doi.org/10.1158/1078-0432.ccr-21-0158
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Autor:
Luisa Manning, Bradley J. Monk, Phylicia Aaron, Evanthia Galanis, Staci Horvath, Rodney P. Rocconi, Thomas J. Herzog, Erin E. Stevens, Adnan R. Munkarah, Meghan Manley, Sharad A. Ghamande, Justin N. Bottsford-Miller, Gladice Wallraven, John Nemunaitis, Adam Walter, Robert L. Coleman, Jeffrey Elder, Leslie L. DeMars, Laura Stanbery, Ernest Bognar
Publikováno v:
Cancer Gene Therapy. 29:369-382
Vigil® is a personalized vaccine that enhances tumor neoantigen expression. We investigated for the first time safety and efficacy of Vigil in combination with atezolizumab in relapsed ovarian cancer (OC) patients. This is a randomized, Phase 1 stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0220c0e11bf3dd7327de5fed5f7a2d3b
https://doi.org/10.1038/s41417-021-00317-5
https://doi.org/10.1038/s41417-021-00317-5